Hematologic immunotherapy & cellular therapy expansion to solid tumors
Key Questions
What is the UCSF in vivo CRISPR CAR-T nanoparticle approach?
UCSF is developing in vivo CRISPR CAR-T nanoparticles that show preclinical superiority over ex vivo methods for both hematologic and solid tumors. This approach delivers CAR-T therapy directly in the body using nanoparticles. It aims to expand immunotherapy to solid tumors effectively.
What are MSK's HIT CAR-T cells for solid tumors?
MSK's HIT CAR-T targets low-CD70 expression in solid tumors. It is part of advancements in hematologic immunotherapy expanding to solids. Related efforts include trilaciclib for leukemia prevention and bispecifics for myeloma and lung cancer.
What are the new CAR-T 'bloodhounds' and their features?
New CAR-T 'bloodhounds' use metabolic tracking for enhanced persistence. They incorporate sequencing and metabolic monitoring to improve durability. Key tracking includes FIH, CRS, toxicity, and persistence metrics.
What is the status of CAR-NKT therapy for endometrial cancer?
CAR-NKT therapy is being developed for endometrial cancer. It represents an expansion of cellular therapies to solid tumors. Preclinical and early data show promise in targeting this malignancy.
What results did TAR-200 show for NMIBC?
TAR-200 achieved an 82% complete response rate in non-muscle invasive bladder cancer (NMIBC). It is part of ongoing advancements like SCAC retifanlimab Phase 3 and Mount Sinai's ICI pathway work. This positions it as a potential new standard.
UCSF in vivo CRISPR CAR-T nanoparticles for heme/solids preclinical superior to ex vivo. MSK HIT CAR-T low-CD70 solids, trilaciclib leukemia prevention, bispecifics myeloma/lung; new CAR-T 'bloodhounds' metabolic tracking, KU Cancer Center myeloma rollout, scRNA-seq heterogeneity; CAR-NKT endometrial; mRNA/dark-genome vaccines; Mount Sinai bladder ICI pathway; SCAC retifanlimab Ph3; TAR-200 NMIBC 82% CR. PubMed Mar22: AI ICI tox agent, catch-bond T-cell eng. START-Trialing boosts EU Ph1 access. Track FIH/durability/CRS/tox/sequencing/metabolic persistence.